Navigation Links
5 Spanish centers join a study for a new leukemia and lymphoma treatment technique
Date:6/3/2009

The Gamida Cell-Teva Joint Venture announced today that five prestigious cord blood transplantations centers in Spain, three in Barcelona and two in Valencia, have joined the ExCell study.

Participating clinical sites include, in alphabetical order:

  • Hospital Clnic of Barcelona, Barcelona: Principal Investigator, Dr. Enric Carreras, MD
  • Hospital Clnico Universitario de Valencia, Valencia: Principal Investigator, Dr. Cristina Arbona, MD
  • Hospital de la Santa Creu i Sant Pau, Barcelona: Principal Investigator, Dr. Jorge Sierra, MD
  • Hospital Germans Trias i Pujol, Barcelona: Principal Investigator, Dr. Christelle Ferra, MD
  • Hospital Universitario La Fe, Valencia: Principal Investigator, Dr. Guillermo Sanz, MD

The trial is assessing the safety and efficacy of StemEx as a treatment for hematological malignancies, including leukemia and lymphoma, in a single arm, global, pivotal marketing authorization trial. StemEx is a graft of expanded stem/progenitor cells, derived from a single unit of umbilical cord blood and transplanted in combination with non expanded cells from the same unit. StemEx is being developed by a Joint Venture of Gamida Cell and Teva Pharmaceutical Industries (NASDAQ: TEVA).

ExCell is a study that gives clinicians the opportunity to explore a new path in the pursuit of a therapeutic treatment for patients with blood cancers. Cord blood can successfully be used to treat leukemia and lymphoma in young children. It stands to reason therefore that the same basic source could also be used to effectively treat adolescents and adults. The ExCell trial provides an opportunity to determine if StemEx can indeed make this a possibility.

Cord blood has less matching requirements than bone marrow or peripheral blood transplants, providing the potential to increase the number of suitable transplant matches and to shorten the time it can take to find a match. However, there are a limited number of stem/progenitor cells in cord blood, enabling a quantity sufficient generally only for pediatric treatment. StemEx employs a technology that expands this small number of cord blood stem/progenitor cells, increasing their therapeutic capacity for transplantation in adolescents and adults.

It is estimated that more than 11,000 patients in the European Union are in need of an allogeneic (from a source outside of the patient's body) hematopoietic (blood) stem cell transplantation. This is an unofficial figure calculated based on the method proposed by the US government's General Accounting Office (GAO) report and The EBMT Activity Survey 2006 on Hematopoietic Stem Cell Transplantation: Focus on the Use of Cord Blood Products.

"We are enthusiastic about working with these five outstanding hospitals in Spain, the esteemed principal investigators and their experienced staves. Together, we hope to demonstrate the advantage of the StemEx transplant for patients," said Dr. David Snyder, vice president of clinical development at Gamida Cell.


'/>"/>

Contact: Alex Argemi
aargemi@clinic.ub.es
34-932-275-700
IDIBAPS - Institut d'Investigacions Biomdiques August Pi i Sunyer
Source:Eurekalert

Related medicine news :

1. PA Department of Health Launches Spanish-Language Smoking Cessation Resource Web Site
2. Few pharmacies can translate prescription labels into Spanish
3. Spanish prostitutes least likely to use condoms
4. Spanish-Speaking OmniPod Customer Support Now Available Around-the-Clock
5. K-State Researcher Finds That the 1918 Spanish Flu Virus Can Infect Swine and Resulted in Current Lineage of H1N1 Swine Influenza Viruses
6. Celebrities, Horses, Music and History Will Unite for 2009 Fiesta of the Spanish Horse Cancer Research Benefit
7. CVS Caremark Launches Spanish Version of Caremark.com
8. Blue Shield of California Launches Online Spanish-Language Service to Help Members Choose a Medical Provider
9. Humana Releases Stay Smart, Stay Healthy Videos in Spanish
10. The Chopra Center Introduces Mind-body Health Programs for Spanish Speakers: Chopra en Espanol Connects Spanish Speakers Worldwide to Deepak Chopra and David Simons Global Message of Wellness
11. Spanish Exercise DVD Helps Latinas Reduce Risk of Preterm Labor
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs surgery ... of Mohs Surgery and to Dr. Russell Peckham for medical and surgical dermatology. , ... for skin cancer. The selective fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey ...
(Date:6/25/2016)... Beach, CA (PRWEB) , ... June 25, 2016 , ... ... UCLA with Magna Cum Laude and his M.D from the David Geffen School of ... Diego and returned to Los Angeles to complete his fellowship in hematology/oncology at the ...
(Date:6/24/2016)... ... ... A recent article published June 14 on E Online details ... to state that individuals are now more comfortable seeking to undergo not only the ... and cheek reduction. The Los Angeles area medical group, Beverly Hills Physicians (BHP) notes ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... Conference and Scientific Sessions in Dallas that it will receive two significant new ... the grants came as PHA marked its 25th anniversary by recognizing patients, medical ...
(Date:6/24/2016)... ... June 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief ... a minimum wage raise to $12 an hour by 2020 and then adjusting it yearly ... lost value of the minimum wage, assure the wage floor does not erode again, and ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... Belgium , June 24, 2016 ... today announced the appointment of Dr. Edward ... as a Non-Executive Director, effective June 23, 2016.Dr. ... Compensation and Nominations and Governance Committees.  As a ... will provide independent expertise and strategic counsel to ...
(Date:6/23/2016)... June 23, 2016 Research and ... Excipients Market by Type (Organic Chemical (Sugar, Petrochemical, Glycerin), ... Topical, Coating, Parenteral) - Global Forecast to 2021" ... The global pharmaceutical excipients market is projected ... CAGR of 6.1% in the forecast period 2016 to ...
(Date:6/23/2016)... 2016 Research and Markets has announced ... report to their offering. ... a favourable commercial environment for MedImmune to enter. The US ... will serve to drive considerable growth for effective anti-influenza medications. ... cap sales considerably, but development is still in its infancy. ...
Breaking Medicine Technology: